INTANGIBLE ASSETS IN INDIAN PHARMACEUTICALS : DISCLOSURE PRACTICES AND IMPACT ON VALUE CREATION

Gugulothu Yakaiah

ISBN 10: 6208447887 / ISBN 13: 9786208447885

Published by LAP LAMBERT Academic Publishing, 2025

About this Item

nach der Bestellung gedruckt Neuware - Printed after ordering - This study analyzed intangible asset (IA) disclosure, trends, and value creation impact in ten Nifty Pharma companies (2015-21). Piramal Enterprises Ltd. led in both mandatory and voluntary disclosures. While most companies showed increasing IA values, their impact on value creation varied. Aurobindo Pharma and Glenmark showed significant IA impact on ROE, ROIC, Tobin's Q, and PB ratio, while Cadila, Divi's, and Dr. Reddy's saw impact on EVA. However, IA had no significant impact on firm value for Biocon, Cipla, Lupin, Piramal, and Sun Pharma in these specific metrics. Overall, IA significantly impacted profitability (ROA, ROE, ROIC, PAT) and firm value (Tobin's Q). Suggestions include improving disclosure for Cadila and Sun Pharma, boosting IA values for Divi's and Lupin, and continuing IA prioritization for Aurobindo and Glenmark to maximize stakeholder value.

Seller Inventory # 9786208447885

Bibliographic Details

• Title: INTANGIBLE ASSETS IN INDIAN PHARMACEUTICALS : DISCLOSURE PRACTICES AND IMPACT ON VALUE CREATION
• Publisher: LAP LAMBERT Academic Publishing
• Publication Date: 2025
• Language: English
• ISBN 10: 6208447887
• ISBN 13: 9786208447885
• Binding: Taschenbuch
• Condition: Neu
• Dimensions: 220W x 150H x 16D millimeters 220 millimeters width by 150 millimeters height by 16 millimeters depth
• Weight: 399 grams

About this title

Synopsis

This study analyzed intangible asset (IA) disclosure, trends, and value creation impact in ten Nifty Pharma companies (2015-21). Piramal Enterprises Ltd. led in both mandatory and voluntary disclosures. While most companies showed increasing IA values, their impact on value creation varied. Aurobindo Pharma and Glenmark showed significant IA impact on ROE, ROIC, Tobin's Q, and PB ratio, while Cadila, Divi's, and Dr. Reddy's saw impact on EVA. However, IA had no significant impact on firm value for Biocon, Cipla, Lupin, Piramal, and Sun Pharma in these specific metrics. Overall, IA significantly impacted profitability (ROA, ROE, ROIC, PAT) and firm value (Tobin's Q). Suggestions include improving disclosure for Cadila and Sun Pharma, boosting IA values for Divi's and Lupin, and continuing IA prioritization for Aurobindo and Glenmark to maximize stakeholder value.